AETHLON MEDICAL INC (AEMD Q4 FY2025 earnings call

• Treated the first 3 patients in oncology trial using Hemopurifier at Australian clinical sites.
• Received regulatory approval in India to initiate similar oncology study.
• Expanded trial protocol to align with evolving standard of care in immunotherapy.
• Preclinical data demonstrate 98.5% removal of platelet-derived extracellular vesicles in simulated Hemopurifier treatments.
• Collaborating with UCSF on long COVID research with findings to be presented at Keystone Symposium.
• Significantly reduced operating expenses through streamlined operations.

As of March 31, 2025, cash balance was approximately $5.5 million. Operating expenses for the year were approximately $9.3 million, a reduction of approximately $3.3 million or 26% compared to prior year, mainly due to lower payroll and related expenses, professional fees, and general and administrative expenses. A noncash charge of $4.6 million related to a warrant inducement offer was recognized, and other income of approximately $324,000 from the employee retention tax credit and $36,000 in related interest income was recorded.

• Will need to keep raising money until able to take government grants or partner with larger company.
• Eventually will need to conduct more equity financing.

• Forward-looking statements are subject to significant risks and uncertainties, with factors that could cause results to differ materially from those anticipated in forward-looking statements found in the company's annual report on Form 10-K, most recent quarterly report on Form 10-Q, and other filings with the SEC.

Q: Given that the company is involved in ongoing clinical studies in Australia, upcoming in India, and long COVID initiative, is the focus still primarily oncology?

A: Our focus remains almost entirely on oncology. The upcoming trial in India is virtually parallel to the Australian trial, and our main focus remains oncology.

Q: With the first 3 patients having been treated in Australia, what is the expected timeline before more robust data is delivered?

A: Once electronic data is finalized and the PIs have signed off, they'll be presented to the Data Safety Monitoring Committee. There's a tentative meeting set up in July. If they like everything, we'll proceed to the next cohort, and we expect to receive preliminary data from the first cohort in about 3 months, with further data later in the summer.

Q: With the approval in India, is there potential to have more than 1 patient per month treated?

A: It's very possible. The logistical treatment of patients doesn't seem to be a constraint; it's more dependent on patient recruitment. If oncologists become more comfortable, more than 1 patient per month is possible.

Q: Regarding grants, is getting grants approved taking longer or is there less grant money available?

A: We haven't had experience with the HHS on the grant side since the regime change. We are familiar with grants, and if we can find one that aligns with our goals, we're for it. Overhead rates might be lower now than in the past, but we'll look for suitable grants if they align with our goals.